Lipid based drug delivery systems (LBDDS) are the most studied and understood bioavailability enhancing solutions
We will review the current OTC remedies for cough, cold and allergy categories and discuss strategies to grow your share on shelf space with innovative dosage forms.
Watch this webinar to learn the key considerations for evaluating available technologies to find the most suitable bioavailability solution.
Lipid-based drug delivery systems provide a reliable solution for poorly soluble molecules
Clarifying the myths surrounding LBDSS which may make drug developers consider it in parallel to other formulation approaches
How to apply lipid based formulation and encapsulate in softgel capsules for a poorly soluble molecule.
How lipid-based drug delivery systems (LBDDS) can be used as a bioavailability enhancing technology.
Development of Cannabis- based drugs can offer a consistent, reliable dose with minimal side effects.
Key development challenges and promising technologies for delivering pediatric formulations.
Latest softgel technology for targeted and controlled delivery of challenging molecules.
Softgel technology for early development to achieve successful formulation and patient outcomes.
Softgel technology has been increasingly applied across a wide range of applications including prescription medicines, consumer health, vitamins & mineral supplements and cosmetics.
Discover an innovative way to deliver challenging and poorly soluble compounds.
Innovative solution for overcoming encapsulation challenges for OTC products.
Address compounds early on in the development process to reduce costs & attrition rates.
Enhance bioavailability, deliver liquid APIs & more with softgel technology.
Expedite the development pathway for early phase compounds and enhance bioavailability.
Boost bioavailability, improve ease & route of administration, and increase patient compliance.
Improve product performance & enhance consumer experience with enteric coating.
Handle small amounts of API or formulation at the early stages of development.
Limit individual variability of type I & II systems with adequate choice of composition.
Improve compatibility with wider range of excipients to enhance bioavailability & stability.
Optimize manufacturing parameters like lower processing temperature & thinner softgel shell.
The toolkit of technologies based upon lipid-based drug delivery systems.
Deliver higher API concentrations in smaller capsules for patient benefits.
OptiPact™ Technology, capabilities for Orphan Drugs & Catalent’s factors of differentiation.
Macromolecules can potentially be converted from injectable to oral drug delivery.
An explanation of OptiGel Bio™ technology as a delivery tool for macromolecule NCE candidates.
RP Scherer Technology can improve timelines and commercialization potential.
New shell and hot-filling that are highly viscous or semi-solid at room temperature